By Amirah Al Idrus
As the quest for COVID-19 treatments continues, the National Institutes of Health (NIH) is starting an adaptive trial to test experimental antibody treatments for the disease. It’s starting with Eli Lilly and AbCellera’s candidate but could add more prospects as the trial goes on.
read more
By Tina Reed
CVS Health earned $3 billion in profit for the first quarter, beating Wall Street expectations.
read more
By Eric Sagonowsky
Unhappy with the price and availability of Gilead’s remdesivir—the only drug with FDA clearance to treat COVID-19—dozens of state attorneys general are calling on the federal government to use its power to bust the company's patents and open up broader production.
read more
By Staff
Beating back the COVID-19 pandemic will take a massive effort by talented, dedicated people in biopharma and beyond. They're working now behind the scenes—scientists, researchers, manufacturing specialists, policy experts and many more—to deliver solutions. We aim to tell their stories in a special feature this fall. And we're looking for your nominations.
read more
By Angus Liu
Moderna's charging between $32 to $37 per dose for its coronavirus shot, dubbed mRNA-1273, for some “smaller-volume” purchasers. That's almost twice what Pfizer and BioNTech offered the U.S. government for 100 million doses of their rival vaccine. Bigger buyers will get a “different ballpark” price, Moderna promised—but didn't say how different.
read more
By Paige Minemyer
The COVID-19 pandemic is highlighting the strengths of Medicare Advantage, Humana executives said Wednesday.
read more
By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner
Moderna's experimental vaccine protected mice in a challenge study, U.S. officials said. Wednesday, pricing for COVID-19 vaccines became clearer with developments from Johnson & Johnson and Moderna. And experts called for an end to harassment of public health officials during the pandemic.
read more
By Healthcare Staff
Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.
read more
By Conor Hale
The massive medtech deal reflects the growing importance of virtual healthcare platforms as the world is caught in the wake of the COVID-19 pandemic.
read more
By Angus Liu
COVID-19 infects a person by first binding to the ACE2 receptor on the surface of healthy cells. Scientists led by University of Illinois, Urbana-Champaign, identified a variant of the receptor that might work as a therapeutic candidate by acting as a decoy to lure the virus away.
read more
By Nick Paul Taylor
Zydus Cadila has completed a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 study. The Indian company said the DNA vaccine was well tolerated in the first stage of the adaptive phase 1/2 trial it initiated last month.
read more
By Heather Landi
A new survey sheds light on how Medicare-eligible seniors have embraced technology for their healthcare needs during the pandemic. Find out how much telehealth visits have soared among this population and the other ways seniors are using digital health tools.
read more
By Angus Liu
Regeneron pulled off a 24% revenue increase on the strength of Eylea and Dupixent sales, as well as a U.S. government contract for its COVID-19 antibodies. The company expects initial clinical virology and biomarker results from the cocktail treatment in September.
read more
By Beth Snyder Bulik
Finding patients with rare diseases is difficult enough, but even more so when diagnostics are needed to identify candidates. Bayer’s pharma chief said it's been a struggle to find patients for its NTRK cancer med Vitrakvi, with prospects not improving during the COVID-19 crisis—and the struggle is shared by other targeted oncology drugs.
read more
